Scholarlink

<p>Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents. Despite advances in surgery and chemotherapy, outcomes remain poor in metastatic cases, with five-year survival rates below 30%. This stagnation highlights the urgent need for novel therapeutic strategies. Growing evidence indicates that the tumor immune microenvironment (TIME) plays a central role in OS progression, metastasis, and resistance to treatment. Immunosuppressive cells, including tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs), dominate the TIME, while cytotoxic T cells often exhibit exhaustion. Stromal barriers, hypoxia, and metabolic constraints further impair immune activity. Recent single-cell and spatial transcriptomic studies reveal that immune and stromal architectures strongly correlate with prognosis and therapeutic response. These features contribute to the limited efficacy of current immunotherapies, including immune checkpoint inhibitors (ICIs) and CAR-T cells. In this review, we summarize the cellular, molecular, and spatial components of the OS TIME, critically evaluate current immunotherapeutic strategies, and highlight emerging translational approaches aimed at overcoming immune resistance and improving clinical outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Targeting the osteosarcoma immune microenvironment for improved immunotherapy and translational applications

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月21日

查看全文
  • Jinlin Cai,
  • Shijie Qiu,
  • Biao Sun,
  • Jianbin Ge,
  • Zhe Yu,
  • Chao Wang

摘要

Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents. Despite advances in surgery and chemotherapy, outcomes remain poor in metastatic cases, with five-year survival rates below 30%. This stagnation highlights the urgent need for novel therapeutic strategies. Growing evidence indicates that the tumor immune microenvironment (TIME) plays a central role in OS progression, metastasis, and resistance to treatment. Immunosuppressive cells, including tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs), dominate the TIME, while cytotoxic T cells often exhibit exhaustion. Stromal barriers, hypoxia, and metabolic constraints further impair immune activity. Recent single-cell and spatial transcriptomic studies reveal that immune and stromal architectures strongly correlate with prognosis and therapeutic response. These features contribute to the limited efficacy of current immunotherapies, including immune checkpoint inhibitors (ICIs) and CAR-T cells. In this review, we summarize the cellular, molecular, and spatial components of the OS TIME, critically evaluate current immunotherapeutic strategies, and highlight emerging translational approaches aimed at overcoming immune resistance and improving clinical outcomes.